WTI Crude Oil Prices Rise Amid Iran Conflict Uncertainty 
GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours 
US Stock Futures Mixed as Fed Holds Rates, Oil Prices Surge, and Big Tech Earnings Drive Market Moves 
China Manufacturing PMI Beats Forecasts in April Amid Weak Domestic Demand 
Oil Prices Ease but Remain Set for Strong April Gains Amid Middle East Tensions 
Panama Defends Port Takeover Amid U.S.-China Tensions and Canal Dispute 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Markets Stay Strong Despite Oil Shock Concerns as Earnings Drive Investor Confidence 
Tokyo Inflation Slows Despite Energy Pressures and BOJ Policy Outlook 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Dollar Holds Near Two-Week High as Fed Hawkish Shift Lifts Yields, Yen Near Intervention Zone 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
U.S. Cybersecurity Pushes Faster Patch Deadlines Amid Rising AI-Driven Threats 
Asian Stocks Slip as Oil Prices Surge and Fed Signals Inflation Risks 
Oil Prices Rise Amid Iran Conflict and Strait of Hormuz Disruption 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Samsung Biologics and Biogen, an American biotechnology company, based in Cambridge, Massachusetts, signed a deal for the transfer of stake in Samsung Boiepis. The South Korean biotech firm headquartered in Songdo, Incheon, is buying all of Biogen’s stake in the biopharma company.
Samsung Bioepis was formed in 2012 via a joint venture between Samsung Biologics and Biogen. The latter owned a 15% stake at first, and in 2018, the percentage was increased to 50% as it extended its controlling rights in the company.
As per The Korea Herald, the acquisition of Biogen’s stake is predicted to help boost Samsung Biologic’s competitiveness in the global bio market. The value of the deal is ₩2.7 trillion or around $2.3 billion.
The total shares acquired are 10,341,852 units, and Samsung Biologics stated that the company’s board of directors approved the transaction. The payments for the stakes are set to be made in installments and will be paid over the next two years.
The full ownership of the shares will take effect once the first payment of $1 billion is completed. It was revealed that it was Biogen that forwarded a request for the buyout deal. Despite the acquisition, both companies said they would continue to work as close partners.
“We are thankful to Samsung Biologics for a productive collaboration since 2012,” Biogen’s chief executive officer, Michel Vounatsos, said in a press release. “We believe biosimilars are essential to help sustain healthcare systems and represent an important value creation opportunity for Biogen.”
With the transaction, Samsung Biologics Co. will take over and be in full control of Samsung Bioepis Co. since the deal is for the entire holdings of Biogen’s shares. Pulse News reported that the transfer of shares is set to take place on April 30, 2022.
Meanwhile, Samsung Bioepis is currently developing five biosimilar drugs that it will be launching worldwide. One of them is just waiting for approval and ready for marketing. The four other drugs are in the third phase of clinical trials. Two of the medicines are for oncology, and three are formulated for autoimmune.
